Tag Archive for: ADC technology

Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the […]

ABL Bio Taps into Synaffix ADC Technology

License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation bioconjugates AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with […]